富祥药业：10月27日召开董事会会议

Group 1 - The core point of the article is that Fuxiang Pharmaceutical (SZ 300497) held its fifth board meeting on October 27, 2025, to review the Q3 2025 report and other documents [1] - For the year 2024, the revenue composition of Fuxiang Pharmaceutical is as follows: 77.94% from pharmaceutical manufacturing, 21.45% from lithium battery electrolyte additives, and 0.61% from CDMO [1] - As of the report, Fuxiang Pharmaceutical has a market capitalization of 5.4 billion yuan [1]